|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GDAP2 |
Gene summary for GDAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GDAP2 | Gene ID | 54834 |
| Gene name | ganglioside induced differentiation associated protein 2 | |
| Gene Alias | MACROD3 | |
| Cytomap | 1p12 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9NXN4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54834 | GDAP2 | P23T-E | Human | Esophagus | ESCC | 4.43e-24 | 5.19e-01 | 0.108 |
| 54834 | GDAP2 | P24T-E | Human | Esophagus | ESCC | 4.37e-08 | 1.22e-01 | 0.1287 |
| 54834 | GDAP2 | P26T-E | Human | Esophagus | ESCC | 2.42e-11 | 1.87e-01 | 0.1276 |
| 54834 | GDAP2 | P27T-E | Human | Esophagus | ESCC | 6.58e-06 | 9.75e-02 | 0.1055 |
| 54834 | GDAP2 | P28T-E | Human | Esophagus | ESCC | 2.67e-13 | 2.46e-01 | 0.1149 |
| 54834 | GDAP2 | P30T-E | Human | Esophagus | ESCC | 2.64e-09 | 3.31e-01 | 0.137 |
| 54834 | GDAP2 | P31T-E | Human | Esophagus | ESCC | 7.67e-10 | 1.92e-01 | 0.1251 |
| 54834 | GDAP2 | P32T-E | Human | Esophagus | ESCC | 1.01e-16 | 2.79e-01 | 0.1666 |
| 54834 | GDAP2 | P36T-E | Human | Esophagus | ESCC | 6.81e-08 | 2.40e-01 | 0.1187 |
| 54834 | GDAP2 | P37T-E | Human | Esophagus | ESCC | 1.75e-11 | 1.25e-01 | 0.1371 |
| 54834 | GDAP2 | P39T-E | Human | Esophagus | ESCC | 6.77e-19 | 2.67e-01 | 0.0894 |
| 54834 | GDAP2 | P40T-E | Human | Esophagus | ESCC | 4.33e-02 | 8.56e-02 | 0.109 |
| 54834 | GDAP2 | P42T-E | Human | Esophagus | ESCC | 3.75e-05 | 1.36e-01 | 0.1175 |
| 54834 | GDAP2 | P44T-E | Human | Esophagus | ESCC | 1.16e-03 | 9.61e-02 | 0.1096 |
| 54834 | GDAP2 | P47T-E | Human | Esophagus | ESCC | 1.32e-21 | 1.20e-01 | 0.1067 |
| 54834 | GDAP2 | P48T-E | Human | Esophagus | ESCC | 6.30e-17 | 1.46e-01 | 0.0959 |
| 54834 | GDAP2 | P49T-E | Human | Esophagus | ESCC | 7.85e-08 | 4.66e-01 | 0.1768 |
| 54834 | GDAP2 | P52T-E | Human | Esophagus | ESCC | 8.79e-15 | 2.52e-01 | 0.1555 |
| 54834 | GDAP2 | P54T-E | Human | Esophagus | ESCC | 4.07e-04 | 1.33e-01 | 0.0975 |
| 54834 | GDAP2 | P56T-E | Human | Esophagus | ESCC | 8.10e-08 | 8.35e-01 | 0.1613 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00325261 | Esophagus | ESCC | response to retinoic acid | 63/8552 | 107/18723 | 4.05e-03 | 1.62e-02 | 63 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GDAP2 | SNV | Missense_Mutation | rs766549019 | c.559C>T | p.Arg187Cys | p.R187C | Q9NXN4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GDAP2 | SNV | Missense_Mutation | novel | c.1159N>A | p.Val387Ile | p.V387I | Q9NXN4 | protein_coding | tolerated(0.14) | probably_damaging(0.997) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| GDAP2 | SNV | Missense_Mutation | novel | c.1111N>G | p.Leu371Val | p.L371V | Q9NXN4 | protein_coding | tolerated(0.17) | benign(0.306) | TCGA-D8-A145-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| GDAP2 | deletion | Frame_Shift_Del | novel | c.526delT | p.Tyr176IlefsTer3 | p.Y176Ifs*3 | Q9NXN4 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| GDAP2 | SNV | Missense_Mutation | novel | c.1082C>A | p.Pro361His | p.P361H | Q9NXN4 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GDAP2 | SNV | Missense_Mutation | novel | c.43A>G | p.Thr15Ala | p.T15A | Q9NXN4 | protein_coding | tolerated(0.16) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GDAP2 | SNV | Missense_Mutation | rs757285829 | c.91N>A | p.Asp31Asn | p.D31N | Q9NXN4 | protein_coding | tolerated(0.34) | benign(0.009) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| GDAP2 | SNV | Missense_Mutation | novel | c.76G>A | p.Glu26Lys | p.E26K | Q9NXN4 | protein_coding | tolerated(0.31) | benign(0.018) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GDAP2 | SNV | Missense_Mutation | novel | c.538N>A | p.Asp180Asn | p.D180N | Q9NXN4 | protein_coding | tolerated(0.15) | possibly_damaging(0.864) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GDAP2 | SNV | Missense_Mutation | novel | c.593A>G | p.Glu198Gly | p.E198G | Q9NXN4 | protein_coding | tolerated(0.06) | benign(0.038) | TCGA-AA-3494-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |